Omtriptolide_HNMR_25569_MedChemExpress

泛素连接酶TRIM在固有免疫信号通路中的研究进展张洪海;张磊【摘要】固有免疫系统通过模式识别受体(PRRs)识别病原入侵微生物保守的病原体相关分子模式(PAMPs),通过一系列的信号转导,诱导炎性细胞因子及I型干扰素的表达.大量的研究表明泛素化在固有免疫信号通路中发挥重要作用.泛素连接酶TRIM(The tripartite motif)属于E3泛素连接酶家族,研究表明其在机体固有免疫反应中发挥重要作用.总结了TRIM家族在Toll样受体(TLRs)、RIG-I样受体(RLRs)以及DNA受体介导的固有信号通路中的功能及其相关分子调控机制,为固有免疫信号通路调控提供新的认识.【期刊名称】《生物学杂志》【年(卷),期】2018(035)002【总页数】4页(P77-80)【关键词】固有免疫;TRIM;信号转导【作者】张洪海;张磊【作者单位】山东大学基础医学院,济南250012;山东大学基础医学院,济南250012【正文语种】中文【中图分类】Q55固有免疫是机体抵抗病原体入侵的第一道防线。

固有免疫应答主要是通过固有免疫细胞的PRRs包括TLRs、RLRs以及DNA受体，识别病原生物的PAMPs，启动一系列信号转导通路，从而诱导炎性细胞因子及I型干扰素的表达，进而启动炎症反应和适应性免疫反应。

蛋白泛素化是指泛素分子在一系列酶包括El泛素激活酶，E2泛素结合酶以及E3泛素连接酶作用下，对靶蛋白进行特异性修饰的过程。

研究表明，蛋白的泛素化修饰在机体的固有免疫应答中发挥重要作用。

TRIM属于E3泛素连接酶的一个家族，在人类中包含70多个成员，结构上高度保守。

TRIM家族涉及多种的生物学过程，比如细胞凋亡、细胞分化、发育、肿瘤发生等。

近年来研究表明，TRIM家族参与天然免疫特别是抗病毒天然免疫调控。

本文主要对TRIM家族在天然免疫信号转导方面新的研究进展进行简要综述。

1 TRIM家族蛋白结构TRIM家族在结构上高度保守，从N端到C端3个保守的结构域依次是RING结构域(RING domain)、1个或2个B-box结构域(B-box domain)、一个卷曲螺旋结构域(Coiled-coil domain)，此外该家族还具有一个可变的C-末端，因此TRIM 家族也称为RBCC家族。

二、是非判断1．蛋白核定位信号(nuclear localization signal)富含碱性氨基酸。

2．有亮氨酸拉链模式的Jun和Fos蛋白质是以二聚体或四聚体的形式结合DNA的。

3．端粒酶以端粒DNA为模板复制出更多的端粒重复单元，以保证染色体末端的稳定性。

4．核纤层蛋白B受体(1amln B receptor，LBR)是内核膜上特有蛋白之一。

5．现在认为gp210的作用主要是将核孔复合体锚区定在孔膜6．由RNA聚合酶I转录的rRNA分子是在胞质中与核糖体蛋白结合成RNP颗粒的，rRNA的转运需要能量。

7．核内有丝分裂指核内DNA多次复制而细胞不分裂，产生的子染色体并行排列，且体细胞内的同源染色体配对，紧密结合在一起成为体积很大的多线染色体。

8．已有的研究表明，组蛋白去乙酰化伴随着对染色质转录的抑制，与活性X染色体相比，雌性哺乳动物失活的X染色体及其组蛋白没有乙酰化修饰。

9．gp210是结构性跨膜蛋白，位于核膜的孔膜区，具有介导核孔复合体与核被膜的连接、将核孔复合体锚定在“孔膜区”的功能。

从而为核孔复合体装配提供一个起始位点。

10．p62是核膜上的功能性核孔复合体蛋白，在脊椎动物中具有两个功能结构域，其c端区可能在核孔复合体功能活动中直接参与核质交换。

11．第一个被确定的NLS来自猴肾病毒(SV40)的T抗原，由7个氨基酸残基构成。

12．常染色质在间期核内折叠压缩程度低，处于伸展状态(典型包装率750倍)，包含单一序列DNA 和中度重复序列DNA(如组蛋白基因和tRNA基因)。

13．异染色质化可能是关闭基因活性的一种途径。

14．T带是C带的反带，显示染色体的末端区。

15．染色质的区间性是通过基因座位控制区( locus control region，LCR)和隔离子(insulator)等顺式作用元件维持的。

三、填空1．细胞核外核膜表面常常附着有颗粒，与相连通。

2．核孔复合体是特殊的跨膜运输蛋白复合体，在经过核孔复合体的主动运输中，核孔复合体具有严格的选择性。

Kit ContentsFlowComp ™ Dynabeads ® contains ~1 × 109 (~10 mg) beads/mL in phosphate buffered saline (PBS), pH 7.4, with 0.1% bovine serum albumin (BSA) and 0.02% sodium azide as a preservative. FlowComp ™ Human CD3 Antibody contains monoclonal CD3 antibody in PBS with 0.5% BSA and 0.02% sodium azide. FlowComp ™ Release Buffer contains modified biotin in 0.1% BSA and 2 mM EDTA.Caution: Sodium azide may react with lead and copper plumbing to form highly explosive metal azides.Product DescriptionFlowComp ™ Human CD3 is intended for positive magnetic isolation of CD3+ T cells from human peripheral bloodmononuclear cells (PBMCs). The isolated cells are highly pure, viable, and bead-free (fig. 1). In the first step, FlowComp ™ Human CD3 Antibody is added and binds to the target cells. In the second step, CD3+ T cells, that have bound the specific antibodies, are captured by the FlowComp ™ Dynabeads ®. In the third and last step, the cells are released from the FlowComp ™ Dynabeads ®.Dynabeads ® FlowComp ™ Human CD3Isolation from PBMCFor research use only. Not for human or animal therapeutic or diagnostic use.Catalog no. 11365D Store at 2˚C to 8˚CRev. Date: February 2012 (Rev. 001)Downstream ApplicationsIsolated cells are bead-free and may be used directly in anydownstream application including flow cytometry. The cells readily proliferate in response toDynabeads ® Human T Activator CD3/CD28 and can be measured by incorporating EdU or in a CFSE assay.Required Materials• Magnet (DynaMag ™ portfolio).See /magnets for recommendations.• Mixer allowing tiltingand rotation of tubes (e.g. HulaMixer ® Sample Mixer).• Isolation Buffer:Ca 2+ and Mg 2+ free PBSsupplemented with 0.1% BSA and 2 mM EDTA.Note: BSA can be replaced by human serum albumin (HSA) or 2% FBS/FCS.• Optional: Flow cytometry antibodies. We recommend using anti-CD3clone UCHT-1 from Caltag Medsystems as primary fluorescent antibody for flow staining of cells after isolation. Optional clones: OKT3, HITa3.• Optional: For viability analysis, SYTOX ® Red is recommended.General Guidelines• Visit /cellisolation and follow ourQuickLinks for recommended sample preparation procedures.• Use a mixer that provides tilting and rotation of the tubes to ensure thatbeads do not settle in the tube.• This product should not be used with the MPC ™-1 magnet(Cat. no. 12001D).• Avoid air bubbles (foaming) during pipetting.• Never use less than the recommended volume of beads.• Carefully follow the recommended pipetting volumes and incubationtimes.• Keep all buffers cold.• To avoid unspecific labeling of cells during flow staining, werecommend using gammaglobulin prior to staining with primary fluorescent antibody.• For better purity, repeat the washing step once or transfer the bead-bound cells to a new tube before adding the FlowComp ™ Release Buffer.• All incubations at room temperature can also be performed at2°C to 8°C.ProtocolThis protocol is intended for isolation of bead-free CD14+ monocytes, starting with 5 × 107 PBMC/test where typically 10–20% are CD14+ monocytes. When working with higher cell numbers/number of tests, scale up all volumes accordingly, as shown in Table 1.Wash the BeadsSee Table 1 for volume recommendations.1. Resuspend the beads in the vial (i.e. vortex for >30 sec, or tilt and rotatefor 5 min).2. Transfer the desired volume of beads to a tube.3. Add the same volume of Isolation Buffer, or at least 1 mL, andresuspend.4. Place the tube in a magnet for 1 min and discard the supernatant.5. Remove the tube from the magnet and resuspend the washed beadsin the same volume of Isolation Buffer as the initial volume of beads (step 2).Prepare Cells• Prepare a PBMC suspension according to “General Guidelines”.Resuspend the cells at 1 × 108 cells/mL in Isolation Buffer. • Prepare approximately 10 mL of Isolation Buffer per 5 × 107cells.PBMC: ~2 × 109Figure 1: Purity of human CD3+ cells isolated from PBMC using Dynabeads ® FlowComp ™Human CD3.For support visit /support or *****************************©2012 Life Technologies Corporation. All rights reserved. The trademarks mentioned herein are the property of Life Technologies Corporation or their respective owners, except where otherwise stated. LIFE TECHNOLOGIES AND/OR ITS AFFILIATE(S) DISCLAIM ALL WARRANTIES WITH RESPECT TO THIS DOCUMENT, EXPRESSED OR IMPLIED, INCLUDING BUT NOT LIMITED TO THOSE OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. IN NO EVENT SHALL LIFE TECHNOLOGIES AND/OR ITS AFFILIATE(S) BE LIABLE, WHETHER IN CONTRACT, TORT, WARRANTY, OR UNDER ANY STATUTE OR ON ANY OTHER BASIS FOR SPECIAL, INCIDENTAL, INDIRECT, PUNITIVE, MULTIPLE OR CONSEQUENTIAL DAMAGES IN CONNECTION WITH OR ARISING FROM THIS DOCUMENT, INCLUDING BUT NOT LIMITED TO THE USE THEREOF .SPEC-06682on labels is the symbol for catalog number.REF Table 1: Volumes for human CD3+ T cells. This protocol is scalable from 1 × 107 to 5 × 108 PBMC. larger tube than recommended in step 14 to successfully remove the biotin in the sample.** When incubating, tilt and rotate the vial so the cells and beads are kept in the bottom of the tube. Do not perform end-over-end mixing if the volume is small relative to the tube size.Description of MaterialsFlowComp ™ Dynabeads ® are uniform, superparamagnetic polystyrene beads (2.8 μm in diameter) coated with modified streptavidin. FlowComp ™ Human CD3 Antibody contains a DSB-X conjugated monoclonal mouse anti-human CD3. FlowComp ™ Release Buffer contains a modified biotin that displaces the modified biotin on the antibody to release cells from the beads.Limited Use Label LicenseThe purchase of this product conveys to the purchaser the limited, nontransferable right to use the purchased amount of the product only to perform internal research for the sole benefit of the purchaser. No right to resell this product or any of itscomponents is conveyed expressly, by implication, or by estoppel. This product is for internal research purposes only and is not for use in commercial applications of any kind, including, without limitation, quality control and commercial services such as reporting the results of purchaser’s activities for a fee or other form of consideration. For information on obtaining additional rights, please contact outlicensing@ or Out Licensing, Life Technologies, 5791 Van Allen Way, Carlsbad, California 92008.Manufactured by Life Technologies AS, Norway. Life Technologies AS complies with the Quality System Standards ISO 9001:2008 and ISO 13485:2003.Limited Product WarrantyLife Technologies Corporation and/or its affiliate(s) warrant their products as set forth in the Life Technologies' General Terms and Conditions of Sale found on Life Technologies' website at /termsandconditions . If you have any questions, please contact Life Technologies at /support .Isolate CellsThis protocol is based on 5 × 107PBMC, but is directly scalable from 1 × 107to 5 × 108 cells, according to Table 1.1. Transfer 500 μL (5 × 107 cells) prepared cells to a tube and add 25 μLFlowComp ™ Human CD3 antibody. 2. Mix well and incubate for 10 min at 2°C to 8°C.3. Wash by adding 2 mL Isolation Buffer and centrifuge for 8 min at350 × g.4. Remove the supernatant and resuspend in 1 mL Isolation Buffer.5. Add 75 μL washed FlowComp ™ Dynabeads ® and mix well(e.g. vortex 2–3 seconds).6. Incubate for 15 min at room temperature under rolling and tilting.7. Add 1 mL isolation buffer, pipet 2–3 times (or vortex 2–3 seconds) andplace the tube in a magnet for 2 min.8. While the tube is still in the magnet, carefully remove and discard thesupernatant containing the CD3 negative cells.9. Repeat steps 7–8 to wash the bead-bound CD3+ cells. These steps arecritical to obtain a high purity of isolated cells.Release Cells10. Resuspend the bead-bound cells in 1 mL Release Buffer.11. Incubate for 10 min with rolling and tilting at room temperature.12. Pipet 10 times to efficiently release the cells and place in a magnet for2 min. Avoid foaming.13. Transfer the supernatant containing the bead-free CD3+ cells to a newtube, and again place on the magnet for 1 min to remove any residual beads. Transfer again the supernatant containing the bead-free cells to a new tube.14. Add 2 mL Isolation Buffer followed by centrifugation for 8 min at350 × g. Discard the supernatant and resuspend the cell pellet in preferred medium.Keep the cells on 2°C to 8°C until further use in downstream applications.Related Products。

293(38):14723-14739.[14]CHEN R,ZOU Y L,MAO D X,et al.The general amino acid controlpathway regulates mTOR and autophagy during serum/glutaminestarvation[J].The Journal of Cell Biology,2014,206(2):173-182.[15]BAR-PELED L,SABATINI D M.Regulation of mTORC1by aminoacids[J].Trends in Cell Biology,2014,24(7):400-406. [16]BEUREL E,GRIECO S F,JOPE R S.Glycogen synthase kinase-3(GSK3):regulation,actions,and diseases[J].Pharmacology&Therapeutics,2015,148:114-131.[17]MIN J,WEI C.Hydroxysafflor yellow A cardioprotection inischemia-reperfusion(I/R)injury mainly via AKT/hexokinaseⅡindependent of ERK/GSK-3βpathway[J].Biomedicine&Pharmacotherapy,2017,87:419-426.[18]CHEN L,LI Q N,LEI L,et al.Dioscin ameliorates cardiachypertrophy through inhibition of the MAPK and AKT/GSK3β/mTOR pathways[J].Life Sciences,2018,209:420-429. [19]阮小芬,沈智杰,薛金贵,等.速效救心丸干预ACS血管重建术后病人的随机㊁双盲㊁安慰剂对照临床研究[J].中西医结合心脑血管病杂志,2019,17(9):1286-1290.[20]王肖龙,刘永明,朱谷晶,等.速效救心丸对急性冠脉综合征患者早期经皮冠状动脉介入效果的影响[J].中国中西医结合杂志,2012,32(11):1483-1487.[21]RUAN X F,LI Y J,JU C W,et al.Exosomes from Suxiao Jiuxinpill-treated cardiac mesenchymal stem cells decrease H3K27demethylase UTX expression in mouse cardiomyocytes in vitro[J].Acta Pharmacologica Sinica,2018,39(4):579-586. [22]YAO W F,HAN X,GE M,et al.N6-methyladenosine(m6A)methylation inischemia-reperfusion injury[J].Cell Death&Disease,2020,11(6):478.[23]FU Y,DOMINISSINI D,RECHAVI G,et al.Gene expressionregulation mediated through reversible m6A RNA methylation[J].Nature Reviews Genetics,2014,15(5):293-306. [24]SCHWARTZ S,MUMBACH M R,JOVANOVIC M,et al.Perturbationof m6A writers reveals two distinct classes of mRNA methylation atinternal and5'sites[J].Cell Reports,2014,8(1):284-296. [25]ZHAO X,YANG Y,SUN B F,et al.FTO-dependent demethylationof N6-methyladenosine regulates mRNA splicing and is requiredfor adipogenesis[J].Cell Research,2014,24(12):1403-1419. [26]ZHENG G Q,DAHL J A,NIU Y M,et al.ALKBH5is a mammalianRNA demethylase that impacts RNA metabolism and mousefertility[J].Molecular Cell,2013,49(1):18-29.[27]ZHANG C Z,SAMANTA D,LU H Q,et al.Hypoxia induces thebreast cancer stem cell phenotype by HIF-dependent andALKBH5-mediated m6A-demethylation of NANOG mRNA[J].Proceedings of the National Academy of Sciences of the UnitedStates of America,2016,113(14):E2047-E2056.[28]CHAO Y H,SHANG J,JI W D.ALKBH5-m6A-FOXM1signalingaxis promotes proliferation and invasion of lung adenocarcinomacells under intermittent hypoxia[J].Biochemical and BiophysicalResearch Communications,2020,521(2):499-506.[29]YANG P P,WANG Q,LIU A H,et al.ALKBH5holds prognosticvalues and inhibits the metastasis of colon cancer[J].PathologyOncology Research,2020,26(3):1615-1623.[30]ZHANG J,GUO S,PIAO H Y,et al.ALKBH5promotes invasionand metastasis of gastric cancer by decreasing methylation ofthe lncRNA NEAT1[J].Journal of Physiology and Biochemistry,2019,75(3):379-389.[31]ZHU H T,GAN X L,JIANG X W,et al.ALKBH5inhibitedautophagy of epithelial ovarian cancer through miR-7and BCL-2[J].Journal of Experimental&Clinical Cancer Research,2019,38(1):163.[32]LUO S K,TONG L.Molecular basis for the recognition ofmethylated adenines in RNA by the eukaryotic YTH domain[J].Proceedings of the National Academy of Sciences of the UnitedStates of America,2014,111(38):13834-13839.(收稿日期:2022-03-01)(本文编辑薛妮)痰湿壅盛型高血压大鼠模型的建立朱甫臻1,尹艳燕1,梁劲杰1,郭嵩然1,徐钟慧2,王灵芝1摘要目的:建立快速稳定的痰湿壅盛型高血压大鼠模型㊂方法:采用不同高脂饮食诱导自发性高血压大鼠(SHR)建立3种痰湿壅盛型高血压大鼠模型㊂将SHR随机分为4组:SHR对照组㊁模型Ⅰ组㊁模型Ⅱ组和模型Ⅲ组,以Wistar大鼠作为正常对照组㊂对照组饲喂普通饲料,造模组分别饲喂高脂饲料1㊁高脂饲料2和高脂饲料3,造模8周㊂造模过程中监测动物行为学变化,全自动生化仪分析血清血脂变化,尾袖法测量血压变化,超声法进行动物心脏结构分析㊂结果:采用高脂饮食1(蛋黄粉10%㊁蔗糖10%㊁猪油15%㊁胆固醇1.2%㊁胆酸钠0.2%,适量的酪蛋白㊁磷酸氢钙㊁石粉等)饲喂SHR而建立的模型Ⅰ组大鼠血压稳定,收缩压维持在167.8 mmHg以上,体质量和低密度脂蛋白胆固醇(LDL-C)增高(P<0.05),高密度脂蛋白胆固醇(HDL-C)降低(P<0.05),造模成功率为100%㊂心脏超声表明,相比Wistar大鼠,SHR对照组和模型Ⅰ组心脏左室收缩末期前壁厚度(LVAWs)㊁左室舒张末期后壁厚度(LVPWd)㊁左心室平均质量(LV Mass A W)增加(P<0.05),左室舒张末期内径(LVIDd)降低(P<0.05);模型Ⅰ组肝脏指数较SHR对照组升高(P<0.05)㊂结论:多种脂肪来源的高脂饲料饮食诱导SHR可建立快速稳定且符合临床要求的痰湿壅盛型高血压大鼠模型㊂关键词高血压;痰湿壅盛型;动物模型;饮食诱导;血脂;实验研究d o i:10.12102/j.i s s n.1672-1349.2023.24.008Establishment of Hypertensive Rat Models with Phlegm-damp AccumulationZHU Fuzhen,YIN Yanyan,LIANG Jinjie,GUO Songran,XU Zhonghui,WANG LingzhiBeijing University of Chinese Medicine,Beijing100029,ChinaCorresponding Author WANG Lingzhi,E-mail:***************.cn;XU Zhonghui,E-mail:******************* Abstract Objective:To establish rapid and stable hypertensive rat models with phlegm-damp accumulation.Methods:Three hypertensive rat models with phlegm-damp accumulation were established by different high-fat diet-induced spontaneously hypertensive rats(SHR).SHR were randomly divided into4groups:SHR control group,modelⅠgroup,modelⅡgroup and modelⅢgroup,and Wistar rats were used as normal control group.Two control groups were fed with normal diet for8weeks,and three model groups were fed with high-fat diet1,high-fat diet2,and high-fat diet3,respectively for8weeks.Behavioral changes of SHR were monitored during the modeling process,serum lipid were analyzed by fully automated biochemistry,and blood pressure changes were detected by the tail-cuff method.Ultrasound method was used to detected the SHR's cardiac structure.Results:The blood pressure of the modelⅠgroup,which was established by feeding with the high-fat diet1(egg yolk powder10%,sucrose10%,lard15%, cholesterol1.2%,sodium cholate0.2%,appropriate amounts of casein,calcium hydrogen phosphate,and stone powder),systolic blood pressure was stably maintained above167.8mmHg.The body weight and low-density lipoprotein cholesterol(LDL-C)increased(P<0.05),and high-density lipoprotein cholesterol(HDL-C)decreased(P<0.05),and the success rate of modeling was100%.Cardiac ultrasound showed that compared with Wistar rats,the left ventricular anterior wall at end-systole(LV A Ws),left ventricular posterior wall at end-diastole (LVPWd),and left ventricular mass average weight(LV Mass AW)increased(P<0.05),and the left ventricular internal diameter at end-diastole(LVIDd)of the SHR control group and the modelⅠgroup decreased(P<0.05),while the liver index of the modelⅠgroup was significantly higher than that of the SHR control group(P<0.05).Conclusion:By a high-fat diet with multiple fat sources HSR could be used to establish rapid and stable hypertensive rat models with obstructed phlegm-damp accumulation that fulfilled clinical requirements. Keywords hypertension;phlegm-damp accumulation;animal models;diet induction;blood lipids;experimental study基金项目国家自然科学基金项目(No.81872972)作者单位 1.北京中医药大学(北京100029);2.中国医学科学院北京协和医学院北京协和医院(北京100730)通讯作者王灵芝,E-mail:***************.cn;徐钟慧,E-mail:*******************引用信息朱甫臻,尹艳燕,梁劲杰,等.痰湿壅盛型高血压大鼠模型的建立[J].中西医结合心脑血管病杂志,2023,21(24):4519-4523.高血压是一种以主动脉收缩压升高为主要特征的常见慢性病[1],严重危害着人类健康㊂2019年世界卫生组织统计,全世界约14亿例高血压病人,控制率仅为14%[2]㊂在我国,大中型城市如北京㊁上海等地高血压发病率约为35.9%和29.1%[3],给我国带来沉重的医疗负担㊂高血压病在中医学上归属于 眩晕 头痛 范畴,按照证候分为痰湿壅盛型㊁肝火亢盛型㊁阴虚阳亢型和阴阳两虚型[4]㊂其中,痰湿壅盛型占比最高,约为17.96%[5]㊂痰湿壅盛型高血压的主要临床表现为头重如裹㊁胸脘痞闷㊁纳呆恶心㊁呕吐痰涎㊁身重困倦㊁少食多寐㊁苔腻㊁脉滑等症状㊂‘景岳全书“提到: 脾为生痰之源 [6],其病机主要为脾运化不利,故生痰浊㊂‘金匮要略“记载: 心下有痰饮,胸胁支满,目眩,苓桂尤甘汤主之 ㊂张仲景提出对痰饮 当以温药和之 ,对饮停中焦之证,应用苓桂术甘汤法健脾温阳利水㊂‘丹溪心法㊃头眩“中云: 头眩,痰挟气虚并火,治痰为主,挟补气药及降火药,无痰则不作眩 ,主张清化痰热㊁补充正气㊂动物模型在研究人类疾病的发病机制㊁发展规律及药物研发中发挥着重要作用㊂目前,常用高血压动物模型主要有:1)自发性高血压动物模型,即自发性高血压大鼠(spontaneous hypertension rats,SHR),由日本京都医学院利用有明显高血压症状的Wistar Kyoto雄性大鼠与带有轻微高血压症状雌性大鼠连续交配培育而成,成年后血压高达200 mmHg以上,高血压自发率为100%㊂2)药物诱导法,常用药物包括醋酸去氧皮质酮(deoxycorticosterone acetate,DOCA)㊁亚硝基左旋精氨酸甲酯(nitro L arginine methyl ester,L-NAME)和血管紧张素Ⅱ(AngⅡ)㊂20世纪70年代,DOCA-盐模型首次用于高血压研究,皮下注射DOCA同时配合高盐饮食,饮用盐水可促进动物高血压的发展[7]㊂Leo等[8]采用L-NAME饲喂Wistar大鼠诱导高血压模型;Cao等[9]采用AngⅡ灌注C57BL6小鼠诱导高血压㊂3)手术诱导法,主要包括一肾一夹[10]㊁两肾一夹[11]㊁两肾两夹法[12]等㊂近年来,痰湿壅盛型高血压动物模型的建立逐渐引起人们关注,该模型的建立常采用陈腾蛟等[13]研究方法,即饲喂Wistar大鼠高脂饲料,该方法存在着造模周期时间长㊁成功率较低等不足,且造模评价指标为血压升高和行为学变化㊂该中医证型的临床特点是低密度脂蛋白胆固醇(LDL-C)升高,高密度脂蛋白胆固醇(HDL-C)降低[14],应进一步完善造模评价指标,以提高造模效率㊂本研究采用不同方法建立快速㊁稳定的痰湿壅盛型高血压大鼠模型,为该病的作用机制和药物研发提供合理的研究基础㊂1材料与方法1.1实验动物Wistar大鼠5只,无特定病原体(SPF)级,雄性,体质量120~150g;购自北京维通利华实验动物技术有限公司,动物合格证号:SCXK(京)2021-0006㊂SHR 共20只,SPF级,雄性,体质量75~105g,由北京维通利华实验动物技术有限公司提供,动物合格证号为SCXK(京)2021-0006㊂所有动物均饲养于北京中医药大学动物房㊂1.2实验饲料动物饲料:普通大鼠维持饲料㊁高脂饲料1(蛋黄粉10%,蔗糖10%,猪油15%,胆固醇1.2%,胆酸钠0.2%,适量的酪蛋白㊁磷酸氢钙㊁石粉等);高脂饲料2(蛋白质24%,碳水化合物41%,猪油24%,酪蛋白㊁糊精㊁蔗糖㊁纤维素㊁豆油㊁多矿㊁多维㊁胆碱);高脂饲料3(蔗糖20%,猪油15%,胆固醇1.2%,胆酸钠0.2%,适量的酪蛋白,磷酸氢钙,石粉)㊂所有饲料均由北京华阜康生物科技股份有限公司提供㊂1.3实验方法1.3.1动物分组及造模SPF级SHR(20只)和Wistar大鼠(5只),适应性喂养1周后,将SHR随机分为SHR对照组㊁模型Ⅰ组㊁模型Ⅱ组和模型Ⅲ组,每组5只;将Wistar大鼠作为正常对照组㊂其间,SHR对照组及正常对照组喂食普通饲料,模型Ⅰ组㊁模型Ⅱ组和模型Ⅲ组分别饲喂高脂饲料1㊁高脂饲料2和高脂饲料3,连续饲喂8周㊂1.3.2观察指标建模期间,每日观察记录大鼠毛色㊁活动程度㊁二便及饮食㊁进水等情况,每周测量体质量㊂血压:采用尾袖法测定大鼠血压[15],无创血压仪型号:BP2000(美国Visitech systems公司);血压测定台37ħ预热5 min,将大鼠放入固定器内适应3~5min,测量安静状态下尾动脉血压,连续测量20次,取平均值,每2周测量1次㊂血脂:眼眶取血,置于无抗凝剂离心管内,室温放置1h,1000ˑg(重力加速度)离心15min,取上清备用㊂采用全自动生化仪(型号:AU480,美国Beckman Coulter公司)测定大鼠血清总胆固醇(TC)㊁三酰甘油(TG)㊁HDL-C㊁LDL-C水平㊂实验结束后,冰上分离大鼠心㊁肝㊁脾㊁肺㊁肾,并称重,按照如下公式计算:脏器指数(%)=脏器质量大鼠体质量ˑ100%1.3.3造模评价标准造模评价标准参照相关文献[13],痰湿型高血压病人常患有高脂血症[14],故将血脂纳入评价标准:1)身型肥胖㊁嗜睡懒动㊁胃纳呆滞㊁不思饮水㊁大便不成形㊁肛门不洁;2)收缩压ȡ140mmHg和(或)舒张压ȡ90mmHg;3)血脂水平变化符合4种高脂血症中的1种,高胆固醇血症,血清TC水平上升;高三酰甘油血症,血清TG水平升高;混合型高脂血症,血清TC㊁TG 水平均增高;低高密度脂蛋白血症,血清HDL-C水平降低㊂1.3.4心脏结构变化大鼠麻醉后,使用超高分辨小动物超声影像系统VevoTM2100(加拿大Visual Sonics公司)测量左室收缩末期内径(left ventricular internal diameter at end-systole,LVIDs)㊁左室舒张末期内径(left ventricular internal diameter at end-diastole,LVIDd)㊁左室收缩末期后壁厚度(left ventricular posterior wall at end-systole,LVPWs)㊁左室舒张末期后壁厚度(left ventricular posterior wall at end-diastole,LVPWd)㊁左室收缩末期前壁厚度(left ventricular anterior wall at end-systole,LVAWs)㊁左室舒张末期前壁厚度(left ventricular anterior wall at end-diastole,LVAWd)㊁左心室平均质量(LV Mass AW)㊁左室射血分数(left ventricular ejection fraction,LVEF)㊁左室短轴缩短率(left ventricular fraction shortening,LVFS)㊂1.4统计学处理采用SPSS19.0分析软件进行数据处理,符合正态分布的定量资料以均数ʃ标准差(xʃs)表示,两组间比较采用t检验,多组间比较采用单因素方差分析ANOVA法㊂采用GraphPad Prism8进行绘图㊂以P< 0.05为差异有统计学意义㊂2结果2.1不同模型大鼠形态学指标造模期间,正常对照组和SHR对照组大鼠毛发洁白㊁柔顺有光泽,精神状态良好,活动度正常,大便黏软有形,肛周洁净㊂各模型组大鼠在造模期间均呈痰湿证表现,包括体质量增加㊁嗜睡萎靡㊁活动度下降㊁饮食饮水减少㊁便溏㊁肛周不洁等㊂从第4周开始,各模型组动物体质量均高于SHR对照组(P<0.05)㊂详见图1㊂2.2不同模型大鼠收缩压变化造模期间,正常对照组收缩压基本维持在131.8~ 150.2mmHg,SHR各组收缩压维持在167.8mmHg以上,且呈现缓慢上升趋势㊂详见图2㊂图1不同模型大鼠体质量变化图2不同模型大鼠收缩压变化2.3不同模型大鼠血脂含量变化模型Ⅰ组LDL-C从第4周开始较SHR对照组升高(P<0.05),HDL-C第8周较SHR对照组降低(P< 0.05);模型Ⅱ组第8周TC和TG均显著增高(P< 0.05),模型Ⅲ组第8周HDL-C水平较SHR对照组显著降低(P<0.05),第4周LDL-C水平较SHR对照组显著升高(P<0.05)㊂详见图3㊂根据临床报道,模型Ⅰ组更符合临床症状[14]㊂2.4不同模型大鼠心脏结构变化为确立痰湿壅盛型高血压大鼠模型,进一步对模型Ⅰ组进行心脏结构分析㊂相较于正常对照组大鼠, SHR对照组大鼠和模型Ⅰ组LVAWs㊁LV Mass AW㊁LVPWd增加(P<0.05),LVIDd降低(P<0.05),模型Ⅰ组LVIDs较SHR对照组降低㊂详见图4㊁表1㊂表明痰湿壅盛型高血压大鼠已出现心脏向心性肥大,提示心脏结构变化可作为痰湿壅盛型高血压模型的评价指标㊂2.5不同模型大鼠脏器指数比较与正常对照组比较,SHR对照组和模型Ⅰ组心脏指数均升高;模型Ⅰ组肝脏指数较SHR对照组升高(P<0.05)㊂提示该饲喂方式对肝脏结构具有一定影响㊂详见表2㊂图3不同模型大鼠血脂含量变化(A为TC;B为TG;C为HDL-C;D为LDL-C㊂与正常对照组同时间比较,*P<0.05;与SHR对照组同时间比较,#P<0.05)图4不同模型大鼠心脏超声结构(短轴)表1不同模型大鼠心脏结构变化(xʃs)组别只数LVAWd(mm)LVAWs(mm)LVIDd(mm)LVIDs(mm)正常对照组5 2.37ʃ0.43 3.43ʃ0.29 6.36ʃ0.62 2.06ʃ0.32 SHR对照组5 2.27ʃ0.18 4.17ʃ0.18① 5.45ʃ0.25① 1.72ʃ0.21模型Ⅰ组5 2.35ʃ0.29 4.11ʃ0.23① 5.07ʃ0.45① 1.04ʃ0.14①②组别LVPWd(mm)LVPWs(mm)LVEF(%)LVFS(%)LV Mass AW(mg)正常对照组 2.51ʃ0.24 4.25ʃ0.1390.79ʃ0.2461.09ʃ0.14975.58ʃ109.71 SHR对照组 4.52ʃ0.28① 6.49ʃ0.37①95.29ʃ0.2872.45ʃ0.371255.49ʃ92.79①模型Ⅰ组 3.20ʃ0.36①② 4.83ʃ0.37②98.11ʃ0.4479.53ʃ1.701126.30ʃ107.27①注:与正常对照组比较,①P<0.05;与SHR对照组比较,②P<0.05㊂表2不同模型大鼠脏器指数比较(xʃs)单位:%组别只数心肝脾肺肾正常对照组50.29ʃ0.04 2.71ʃ0.180.17ʃ0.060.37ʃ0.070.35ʃ0.05 SHR对照组50.39ʃ0.02① 2.82ʃ0.130.15ʃ0.010.41ʃ0.050.36ʃ0.03模型Ⅰ组50.36ʃ0.02① 3.40ʃ0.11①②0.13ʃ0.010.36ʃ0.010.32ʃ0.02注:与正常对照组比较,①P<0.05;与SHR对照组比较,②P<0.05㊂3讨论高血压发病机制复杂多样,包括系统性代谢紊乱㊁肾脏代谢[16]㊁肥胖症[17]㊁糖尿病[18]㊁内皮功能失调[19]㊁氧化应激及炎症[20]等㊂基于中医体质学,高血压的影响因素包括平和质㊁气虚质㊁阳虚质㊁阴虚质㊁痰湿质㊁湿热质㊁血瘀质㊁气郁质㊁特禀质,其中痰湿质㊁阴虚质和气虚质为主要影响因素㊂痰湿质是由气血津液运化失司,淤积形成痰,以浊重黏滞为主要特征的一种体质[21]㊂痰湿既是高血压的病理产物,又是其致病因素,在高血压发生过程中发挥重要作用,是高血压的常见证型之一[22]㊂中医学认为血脂异常是 痰浊 重要的生理生化指标和物质基础㊂高脂血症是一种由脂质代谢异常引起的代谢性疾病,通常以TG㊁TC㊁LDL-C增加和/或HDL-C 降低进行判断㊂有研究表明,肾脏中脂质堆积阻碍肾素分泌,导致血压异常[23]㊂肥胖是高血压发生的重要因素,中医学认为 肥人多痰湿 ,肥胖㊁超重等因素可增加高血压发生的风险[24],长期高脂饮食导致SD大鼠内脏脂肪增加㊁平均动脉压升高,发生内皮功能障碍[25]㊂本研究结果表明,高脂饮食使SHR体质量显著增加,且SHR血压增加快且稳定,收缩压维持在167.8 mmHg以上,达到造模中血压标准;Wistar大鼠与SHR脂肪代谢方面存在着一定差异,SHR的HDL-C 水平低于Wistar大鼠(P<0.05),符合痰湿壅盛型高血压的模型要求,表明以SHR建立痰湿壅盛型高血压大鼠模型省时高效㊂目前常用高脂饮食诱导法建立痰湿壅盛型高血压大鼠模型,其中高脂配方中的脂肪主要来源为猪油[26-27],来源单一,存在一定的局限性;应用高脂高糖配方可诱导痰湿型高血压模型[28-29]㊂本研究采用3种不同的高脂饲料,其中高脂饲料2为经典肥胖高脂饲料配方,高脂饲料3为常用高脂高糖饲料配方,高脂饲料1中添加了10%蛋黄粉,导致SHR的HDL-C㊁LDL-C 水平升高,符合临床痰湿壅盛型的特点㊂说明丰富的脂肪种类诱导的动物模型更符合临床痰湿型,今后可进一步将HDL-C及LDL-C水平纳入建模评判标准㊂综上所述,本研究采用高脂饲料1(蛋黄粉10%㊁蔗糖10%㊁猪油15%㊁胆固醇1.2%㊁胆酸钠0.2%,适量的酪蛋白㊁磷酸氢钙㊁石粉等)饲喂SHR建立了快速稳定的痰湿壅盛型高血压大鼠模型,可为今后相关疾病的作用机制解析和药物研发提供可靠的实验基础㊂参考文献:[1]JAHANDIDEH F,WU J P.Perspectives on the potential benefitsof antihypertensive peptides towards metabolic syndrome[J].International Journal of Molecular Sciences,2020,21(6):2192. [2]World Health Organization.Guideline for the pharmacologicaltreatment of hypertension in adults[EB/OL].(2021-08-24)[2022-10-21].https://www.who.int/publications/i/item/9789240033986.[3]中国高血压管理指南编写组,中国高血压联盟,中国心脏病学会,等.中国高血压防治指南(2018年修订版)[J].中国心血管杂志,2019,24(1):24-56.[4]中药新药治疗高血压病的临床研究指导原则(摘编之一)[J].中医药临床杂志,2007,19(2):118-119.[5]周明超,王清海.脉胀病辨证分型规律的文献研究[J].中华中医药杂志,2017,32(8):3511-3514.[6]柳亚平,潘桂娟.‘景岳全书“痰证诊治研讨[J].中华中医药杂志,2007,22(7):427-429.[7]BASTING T,LAZARTIGUES E.DOCA-salt hypertension:anupdate[J].Current Hypertension Reports,2017,19(4):32. [8]LEO M D,KANDASAMY K,SUBRAMANI J,et al.Involvement ofinducible nitric oxide synthase and dimethyl argininedimethylaminohydrolase in Nω-nitro-L-arginine methyl ester(L-NAME)-induced hypertension[J].Cardiovascular Pathology,2015,24(1):49-55.[9]CAO X,LUO T,LUO X,et al.Resveratrol prevents AngⅡ-inducedhypertension via AMPK activation and RhoA/ROCK suppressionin mice[J].Hypertension Research,2014,37(9):803-810. [10]原卫清,王颢,吕卓人. 一肾一夹 高血压大鼠动脉平滑肌细胞钠泵α亚单位的基因表达[J].高血压杂志,2001,9(2):140-142. [11]傅辰生,刘春凤,徐少伟,等.罗格列酮对两肾一夹高血压大鼠的降压作用[J].复旦学报(医学版),2006,33(6):807-809;818. [12]周四桂,高洁,符佳佳,等.两肾两夹高血压与自发性高血压大鼠左心室肥厚的比较[J].蛇志,2008,20(2):94-98.[13]陈腾蛟,徐男.自发性高血压痰湿壅盛型大鼠动物模型的构建和分析评价[J].药学研究,2015,34(9):503-506.[14]杨红,金艳蓉,杨海燕.高血压病血脂异常与辨证分型的关系[J].疑难病杂志,2002,1(4):221-222.[15]CHEN W H,LIU T H,LIANG Q E,et al.miR-1283contributes toendoplasmic reticulum stress in the development of hypertensionthrough the activating transcription factor-4(ATF4)/C/EBP-homologous protein(CHOP)signaling pathway[J].MedicalScience Monitor,2021,27:e930552.[16]TIAN Z M,LIANG M Y.Renal metabolism and hypertension[J].Nature Communications,2021,12:963.[17]SERAVALLE G,GRASSI G.Obesity and hypertension[J].Pharmacological Research,2017,122:1-7.[18]CHEUNG B M Y,LI C.Diabetes and hypertension:is there acommon metabolic pathway?[J].Current AtherosclerosisReports,2012,14(2):160-166.[19]KONUKOGLU D,UZUN H.Endothelial dysfunction andhypertension[M]//Advances in Experimental Medicine andBiology.Cham:Springer International Publishing,2016:511-540.[20]DINH Q N,DRUMMOND G R,SOBEY C G,et al.Roles ofinflammation,oxidative stress,and vascular dysfunction inhypertension[J].Bio Med Research International,2014,2014:406960.[21]王琦,叶加农,朱燕波,等.中医痰湿体质的判定标准研究[J].中华中医药杂志,2006,21(2):73-75.[22]丛德毓.痰湿质与高血压病形成的相关性研究[J].长春中医药大学学报,2012,28(1):74.[23]GAI Z B,WANG T Q,VISENTIN M,et al.Lipid accumulation andchronic kidney disease[J].Nutrients,2019,11(4):722. [24]中华医学会心血管病学分会高血压学组.肥胖相关性高血压管理的中国专家共识[J].中华心血管病杂志,2016,44(3):212-219. [25]DA SILVA A A,KUO J J,TALLAM L S,et al.Role of endothelin-1in blood pressure regulation in a rat model of visceral obesityand hypertension[J].Hypertension,2004,43(2):383-387. [26]贾磊,杨雨民,周芸慧,等.半夏白术天麻汤对痰湿壅盛型高血压大鼠血清TC㊁TG㊁LDL-C㊁HDL-C含量的影响[J].中西医结合心血管病电子杂志,2019,7(10):7-8;10.[27]徐男,时海燕,王淑玲,等.基于正交试验配合多药效指标综合评价半夏白术天麻汤治疗痰湿壅盛型高血压的有效组分配伍[J].中国实验方剂学杂志,2018,24(21):7-13.[28]何茂,许万枫,苏洁,等.复方野菊花提取物对高脂高糖饮酒致肝旺痰阻型高血压大鼠的作用研究[J].中药新药与临床药理,2019,30(2):156-161.[29]王娇,欧阳丽娟,陈慧.葛根和盐泽泻不同配伍比例对长期高糖高脂饮食致高血压大鼠的影响[J].临床合理用药杂志,2022,15(6):9-12.(收稿日期:2023-01-19)(本文编辑薛妮)。